<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151275">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01799889</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-339-0102</org_study_id>
    <nct_id>NCT01799889</nct_id>
  </id_info>
  <brief_title>A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies</brief_title>
  <official_title>A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the efficacy, safety, tolerability, and pharmacodynamics of
      GS-9973. Up to 280 participants will be enrolled who have one of the following hematological
      tumor types: relapsed or refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma
      (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent
      non-Hodgkin lymphomas (iNHL; including lymphoplasmacytoid lymphoma/ Waldenström
      macroglobulinemia [LPL/WM], small lymphocytic lymphoma [SLL], or marginal zone lymphoma
      [MZL]).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS will be evaluated from date of enrollment until the date of first documented progression or date of death from any cause, whichever were to occur first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety: laboratory data, adverse events (AEs), and treatment-emergent AEs will be collected. Safety will be assessed by grading of laboratory values and AEs according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective response rate (ORR). ORR will be determined from the subjects' best response during GS-9973 therapy and will include complete response (CR) and partial response (PR) (or very good partial response [VGPR] or minor response [MR] for subjects with LPL/WM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of response (DOR). DOR will be defined as time from the first response (CR or PR [or VGPR or MR for subjects with LPL/WM]) is achieved until the earlier of the first documentation of definitive disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to response (TTR). TTR will be defined as time from the first dose of GS-9973 to the first time the response (CR or PR [or VGPR or MR for subjects with LPL/WM]) is achieved.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <condition>Indolent Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>GS-9973</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive open label 800 mg GS-9973 orally dosed twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9973</intervention_name>
    <description>800 mg of GS-9973 orally dosed twice daily</description>
    <arm_group_label>GS-9973</arm_group_label>
    <other_name>GS 9973</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of B-cell iNHL, DLBCL, MCL, or CLL as documented by medical records and
             with histology based on criteria established by the World Health Organization

          -  For institutions that have Phase 3 protocols studying idelalisib (GS-1101); subjects
             with malignancies being studied in these protocols must have failed screening in the
             respective idelalisib protocol

          -  Prior treatment for lymphoid malignancy

          -  Presence of radiographically measurable lymphadenopathy or extranodal lymphoid
             malignancy

          -  All acute toxic effects of any prior antitumor therapy resolved to Grade ≤ 1 before
             the start of study drug

          -  Karnofsky performance status of ≥ 60

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Known histological transformation from iNHL or CLL to an aggressive form of NHL (ie,
             Richter transformation)

          -  Known active central nervous system or leptomeningeal lymphoma

          -  Presence of known intermediate- or high-grade myelodysplastic syndrome

          -  Current therapy with agents that reduce gastric acidity, including but not limited to
             antacids, H2 inhibitors, and proton pump inhibitors

          -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
             start of study drug

          -  Ongoing liver injury

          -  Ongoing or recent hepatic encephalopathy

          -  Ongoing drug-induced pneumonitis

          -  Ongoing inflammatory bowel disease

          -  Ongoing alcohol or drug addiction

          -  Pregnancy or breastfeeding

          -  History of prior allogeneic bone marrow progenitor cell or solid organ
             transplantation

          -  Ongoing immunosuppressive therapy

          -  Concurrent participation in an investigational drug trial with therapeutic intent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Abella, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alma Araneta</last_name>
    <email>alma.araneta@gilead.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Flordeliza Melchor-Khan</last_name>
    <email>flordeliza.melchorkhan@gilead.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Busby</last_name>
      <phone>205-934-0337</phone>
      <email>lizbusby@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Andres Forero-Torres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Miller</last_name>
      <phone>520-886-0206</phone>
      <email>janice.miller@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Julie Klinker</last_name>
      <phone>520-886-0206</phone>
      <email>julie.klinker@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Di Simone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Saint Joseph Medical Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaemee Bautista</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>63033</phone_ext>
      <email>jbautista@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Pennie Lam</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>63192</phone_ext>
      <email>hilam@coh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Wood</last_name>
      <phone>858-939-5067</phone>
      <email>Cathy.wood@sharp.com</email>
    </contact>
    <contact_backup>
      <last_name>Karen Graham</last_name>
      <phone>858-939-5068</phone>
      <email>Karen.graham@sharp.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alfred Saleh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, LLP</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Harsh</last_name>
      <phone>303-388-4876</phone>
      <email>heather.harsh@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Bobbie Donnachaidh</last_name>
      <phone>303-388-4876</phone>
      <email>bobbie.donnachaidh@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Andorsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Central Connecticut</name>
      <address>
        <city>Southington</city>
        <state>Connecticut</state>
        <zip>06489</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Turney</last_name>
      <phone>860-621-9316</phone>
      <email>mjt2716@sbcglobal.net</email>
    </contact>
    <investigator>
      <last_name>Peter Byeff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer - Colonial</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Solak</last_name>
      <phone>239-938-0800</phone>
      <email>nsolak@flcancer.com</email>
    </contact>
    <contact_backup>
      <last_name>Stacy Gilmore</last_name>
      <phone>239-938-0800</phone>
      <email>sgilmore@flcancer.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lowell Hart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deneise Francis</last_name>
      <phone>954-965-6390</phone>
      <email>Dfrancis@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Alvaro Alencar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanine Richmond</last_name>
      <phone>904-202-7070</phone>
      <email>Jeanine.richmond@bmcjax.com</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Canto</last_name>
      <phone>904-202-7073</phone>
      <email>andrea.canto@bmcjax.com</email>
    </contact_backup>
    <investigator>
      <last_name>Troy Guthrie, Jr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Williams</last_name>
      <phone>770-496-9419</phone>
      <email>Robin.Williams@gacancer.com</email>
    </contact>
    <contact_backup>
      <last_name>Charles Sykes</last_name>
      <phone>478-745-6130</phone>
      <phone_ext>x128</phone_ext>
      <email>charles.sykes@gacancer.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mansoor N Saleh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gwinnett Hospital System Dba The Center for Cancer Care</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Frank</last_name>
      <phone>678-533-1567</phone>
      <email>kfrank@suburban-hemonc.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Hagenstad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Center</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Gilley</last_name>
      <phone>770-281-5131</phone>
      <email>mgilley@ngoc.com</email>
    </contact>
    <contact_backup>
      <last_name>Latanya Alphonse</last_name>
      <phone>770-281-5118</phone>
      <email>lalphonse@ngoc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Hermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pian Moy</last_name>
      <phone>847-827-9060</phone>
      <email>pian.moy@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Heather Lee</last_name>
      <phone>847-259-0624</phone>
      <email>heather.lee@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Leonard Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Clinic, PLLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evie Key</last_name>
      <phone>225-761-3951</phone>
      <email>eviekey@hoc.brcoxmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Probst</last_name>
      <phone>225-761-3952</phone>
      <email>eviekey@hoc.brcoxmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Castine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Loiselle</last_name>
      <phone>617-636-2683</phone>
      <email>cloiselle@tuftsmedicalcenter.org</email>
    </contact>
    <contact_backup>
      <last_name>Shrikar Rajagopal</last_name>
      <phone>617-636-2883</phone>
      <email>srajagopal@tuftsmedicalcenter.org</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Willbee</last_name>
      <phone>734-936-3879</phone>
      <email>tpelton@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erica Chapman</last_name>
      <phone>734-232-0716</phone>
      <email>echapman@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Lebovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Houde</last_name>
      <phone>313-576-9831</phone>
      <email>houdec@karmanos.org</email>
    </contact>
    <contact_backup>
      <last_name>Courtney Wolf</last_name>
      <phone>313-576-9376</phone>
      <email>wolfc@karmanos.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jay Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Green</last_name>
      <phone>651-735-7414</phone>
      <email>lori.green@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Holly Desma</last_name>
      <phone>651-735-7414</phone>
      <email>hollyjo.desma@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Flynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy McBeth</last_name>
      <phone>601-288-2495</phone>
      <email>tmcbeth@forrestgeneral.com</email>
    </contact>
    <investigator>
      <last_name>John Hrom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology West PC dba Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Marie Fredrichs</last_name>
      <phone>402-691-6971</phone>
      <email>afredrichs@nebraskacancer.com</email>
    </contact>
    <contact_backup>
      <last_name>Faye Park</last_name>
      <phone>402-691-6971</phone>
      <email>fpark@nebraskacancer.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stefano Tarantolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Northern New Jersey</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle MacKenzie</last_name>
      <phone>973-538-3593</phone>
      <phone_ext>2338</phone_ext>
      <email>mmackenzie@hoannj.com</email>
    </contact>
    <investigator>
      <last_name>Charles Farber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Given</last_name>
      <phone>513-751-2273</phone>
      <phone_ext>27110</phone_ext>
      <email>ngiven@ohcare.com</email>
    </contact>
    <contact_backup>
      <last_name>Shaundra Izzo</last_name>
      <phone>513-751-2273</phone>
      <email>sizzo@ohcare.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Essell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cornman</last_name>
      <phone>216-444-4432</phone>
      <email>Cornmas@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Basel Rouphail</last_name>
      <phone>216-636-5643</phone>
      <email>rouphab@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mitchell Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Williamette Valley Cancer Center and Research Institute</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wade Carson</last_name>
      <phone>541-741-3451</phone>
      <email>wade.carson@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Betty Olguin</last_name>
      <phone>541-741-3451</phone>
      <email>betty.goracke-olguin@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeff Sharman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates, PA</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Prairie Lakes Health Care System, Inc.</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Campbell</last_name>
      <phone>605-882-6800</phone>
      <email>lisa.campbell@prairielakes.com</email>
    </contact>
    <contact_backup>
      <last_name>Valerie Jensen</last_name>
      <phone>605-882-6800</phone>
      <email>valerie.jensen@prairielakes.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bipinkumar Amin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jones Clinic PC</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Morningstar</last_name>
      <phone>901-685-5969</phone>
      <email>cmorningstar@jonescancerclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Lori Lynch</last_name>
      <phone>901-685-5969</phone>
      <email>llynch@jonescancerclinic.com</email>
    </contact_backup>
    <investigator>
      <last_name>Clyde Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Colding</last_name>
      <phone>615-524-4127</phone>
      <email>sara.colding@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Ian Flinn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arlington Cancer Center</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Rogers</last_name>
      <phone>817-261-4906</phone>
      <email>nikkirogers@texashealth.org</email>
    </contact>
    <investigator>
      <last_name>Alfred DiStefano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Shaw</last_name>
      <phone>512-614-5935</phone>
      <email>Andrea.Shaw@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Hendrix</last_name>
      <phone>512-341-8724</phone>
      <email>lauren.hendrix@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Melear, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Medical City Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Waldrop</last_name>
      <phone>972-566-4291</phone>
      <email>rhonda.waldrop@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Karen Holck</last_name>
      <phone>972-566-4291</phone>
      <email>karen.holck@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Savin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Sottosanti</last_name>
      <phone>817-759-7023</phone>
      <email>msottosanti@txcc.com</email>
    </contact>
    <contact_backup>
      <last_name>Robin Rutt</last_name>
      <phone>817-759-7000</phone>
      <email>rrutt@txcc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ray Page, DO, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Network of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Lopez</last_name>
      <phone>210-656-7177</phone>
      <email>Maria.lopez2@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Julie MacLaren</last_name>
      <phone>210-656-7177</phone>
      <email>Julie.maclaren@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Chapuran</last_name>
      <phone>703-280-5390</phone>
      <email>lisa.chapuran@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Janine Prime</last_name>
      <phone>703-280-5390</phone>
      <email>janine.prime@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dipti Patel-Donnelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Nilson</last_name>
      <phone>804-288-7159</phone>
      <email>dnilson@vacancer.com</email>
    </contact>
    <investigator>
      <last_name>James Khatcheressian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Basin Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Johansen, MD</last_name>
      <phone>509-783-4637</phone>
      <phone_ext>1</phone_ext>
      <email>hjohansen@cbho.org</email>
    </contact>
    <contact_backup>
      <last_name>Dina Kasper</last_name>
      <phone>(509) 783-4637</phone>
      <email>dkasper@cbho.org</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Rado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Blankenship</last_name>
      <phone>206-288-1172</phone>
      <email>kblanken@seattlecca.org</email>
    </contact>
    <contact_backup>
      <last_name>Alisa Bradford</last_name>
      <phone>206-288-6747</phone>
      <email>abradfor@seattlecca.org</email>
    </contact_backup>
    <investigator>
      <last_name>Andrei Shustov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, PC</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Papenfuse</last_name>
      <phone>360-449-6521</phone>
      <email>susan.papenfuse@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Judith Welch</last_name>
      <phone>360-449-6522</phone>
      <email>Judith.welch@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kathryn Kolibaba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Lapsley</last_name>
      <phone>509-574-3493</phone>
      <email>mark.lapsley@yvmh.org</email>
    </contact>
    <contact_backup>
      <last_name>Beth Parker</last_name>
      <phone>509-574-3493</phone>
      <email>beth.parker@yvmh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Boyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Marsh-Gray</last_name>
      <phone>705-728-9090</phone>
      <phone_ext>43340</phone_ext>
      <email>marshk@rvh.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Michele Harris</last_name>
      <phone>705-728-9090</phone>
      <phone_ext>43342</phone_ext>
      <email>harrism@rvh.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Derek Nay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis-Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara Lau</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>8325</phone_ext>
      <email>clau@jgh.mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Monica Dobocan</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>8326</phone_ext>
      <email>mdobocan@jgh.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sarit Assouline</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GS-US-339-0102</keyword>
  <keyword>SYK inhibitor</keyword>
  <keyword>GS-9973</keyword>
  <keyword>GS 9973</keyword>
  <keyword>CLL</keyword>
  <keyword>leukemia</keyword>
  <keyword>lymphoma</keyword>
  <keyword>MCL</keyword>
  <keyword>DLBCL</keyword>
  <keyword>iNHL</keyword>
  <keyword>FL</keyword>
  <keyword>MZL</keyword>
  <keyword>LPL</keyword>
  <keyword>SLL</keyword>
  <keyword>WM</keyword>
  <keyword>Waldenström's macroglobulinemia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
